Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Janssen“
Suchtreffer
Begriffe & Kennungen
Byannli (previously Paliperidone Janssen-Cilag International)
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.1 Therapeutic indications · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.3 Contraindications · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.3 · Hypersensitivity to the active substance, to risperidone or to any of the excipients listed in section 6.1.
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · 10 Concomitant use of BYANNLI with risperidone or oral paliperidone
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · 9 Potential for BYANNLI to affect other medicines
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be obs
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Caution is advised if paliperidone is combined with other medicinal products known to lower the seizure thresh
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Caution is advised when prescribing BYANNLI with medicinal products known to prolong the QT interval, e.g., cl
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Co-administration of a single dose of an oral paliperidone prolonged-release tablet 12 mg with divalproex sodi
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Co-administration of oral paliperidone prolonged-release once daily with carbamazepine 200 mg twice daily caus
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Co-administration of oral paliperidone prolonged-release tablets at steady-state (12 mg once daily) with dival
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Concomitant use of BYANNLI with psychostimulants
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Given the primary central nervous system (CNS) effects of paliperidone (see section 4.8), BYANNLI should be us
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but the
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · No interaction study between BYANNLI and lithium has been performed, however, a pharmacokinetic interaction is
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicinal product
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Paliperidone may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed
Eintrag öffnen